LLY

1,011.12

+1.64%↑

JNJ

229.43

+0.85%↑

ABBV

207.16

-1.57%↓

UNH

399.42

+1.64%↑

AZN

186

+0.19%↑

LLY

1,011.12

+1.64%↑

JNJ

229.43

+0.85%↑

ABBV

207.16

-1.57%↓

UNH

399.42

+1.64%↑

AZN

186

+0.19%↑

LLY

1,011.12

+1.64%↑

JNJ

229.43

+0.85%↑

ABBV

207.16

-1.57%↓

UNH

399.42

+1.64%↑

AZN

186

+0.19%↑

LLY

1,011.12

+1.64%↑

JNJ

229.43

+0.85%↑

ABBV

207.16

-1.57%↓

UNH

399.42

+1.64%↑

AZN

186

+0.19%↑

LLY

1,011.12

+1.64%↑

JNJ

229.43

+0.85%↑

ABBV

207.16

-1.57%↓

UNH

399.42

+1.64%↑

AZN

186

+0.19%↑

Home・Aandelen Lijst・Pulse Biosciences Inc

Pulse Biosciences Inc

Open

SectorGezondheidszorg

23.68 8.38

Buy Sell

Overzicht

Wijziging aandelenprijs

24u

Huidig

Min

21.85

Max

23.86

Belangrijke statistieken
By Trading Economics
Inkomsten	2M -17M
Verkoop	137K 401K
EPS	-0.18
Winstmarge	-6,603.409
Werknemers	116
EBITDA	-1.4M -19M

Aanbevelingen
By TipRanks
Aanbevelingen	Buy
12 Maanden Prognose	+28.76% upside

Marktinformatie
By TradingEconomics
Marktkapitalisatie	-173M 1.4B
Vorige openingsprijs	15.3
Vorige sluitingsprijs	23.68

Nieuwssentiment

By Acuity

50%

150 / 346 Rangschikking in Healthcare

Technische score

By Trading Central

Vertrouwen

Very Strong Bearish Evidence

16.59 / 17.17 Steun & Weerstand

Pulse Biosciences Inc Grafiek

Eerdere prestaties zijn geen betrouwbare indicator voor toekomstige resultaten.

Gerelateerd nieuws

12 mei 2026, 22:50 UTC

Winsten

Commonwealth Bank of Australia Increases Provisions as 3Q Profit Slips

12 mei 2026, 22:49 UTC

Winsten

Aristocrat Leisure Raises Midyear Dividend, Swells Share Buyback Program

12 mei 2026, 22:32 UTC

Winsten

JBS 1Q Profit Slides Amid Rising Cattle Costs -- Update

12 mei 2026, 23:48 UTC

Marktinformatie

Nikkei May Decline Amid Uncertainty Over Iran Conflict -- Market Talk

12 mei 2026, 22:57 UTC

Marktinformatie

Winsten

JBS Says Consumers Are Looking to Pork for Affordable Protein -- Market Talk

12 mei 2026, 22:26 UTC

Winsten

Aristocrat Leisure to Increase On-Market Share Buyback by A$1 Billion

12 mei 2026, 22:25 UTC

Winsten

Aristocrat Leisure 1H Normalized Pretax Profit A$997.3 Million, Up 9.4% on Year

12 mei 2026, 22:25 UTC

Winsten

Aristocrat Leisure Interim Dividend A$0.50/Security

12 mei 2026, 22:24 UTC

Winsten

Aristocrat Leisure 1H Revenue From Continuing Operations A$3.03 Billion, Down 0.2% on Year

12 mei 2026, 22:23 UTC

Winsten

Aristocrat Leisure 1H Net Profit From Discontinued Operations A$7.0 Million

12 mei 2026, 22:23 UTC

Winsten

Aristocrat Leisure 1H Net Profit From Continuing Operations A$798.5 Million, Up 56%

12 mei 2026, 22:19 UTC

Winsten

CBA: Total Provision Coverage Ratio 1.57%>CBA.AU

12 mei 2026, 22:14 UTC

Winsten

CBA: Business Lending Continued to Grow Above System>CBA.AU

12 mei 2026, 22:14 UTC

Winsten

CBA Had 1.4M Business Transaction Accounts at March 31, Up 7% on Year>CBA.AU

12 mei 2026, 22:13 UTC

Winsten

CBA Household Deposits Grew A$38B in 12 Months Through March>CBA.AU

12 mei 2026, 22:12 UTC

Winsten

CBA Home Loan Balances Grew A$41B in 12 Months Through March>CBA.AU

12 mei 2026, 22:12 UTC

Winsten

CBA 3Q New Home Loan Funding A$45B>CBA.AU

12 mei 2026, 22:11 UTC

Winsten

Correct: JBS NV 1Q EPS 20c, Not 21c >JBS

12 mei 2026, 22:11 UTC

Winsten

CBA: CET1 Level 2 Capital Ratio 11.6%>CBA.AU

12 mei 2026, 22:10 UTC

Winsten

CBA: Customer Deposit Funding Ratio 79%>CBA.AU

12 mei 2026, 22:09 UTC

Winsten

CBA: Underlying Portfolio Credit Quality Remains Sound>CBA.AU

12 mei 2026, 22:09 UTC

Winsten

CBA: Higher Collective Provisions Reflect Geopolitical, Macroeconomic Uncertainty >CBA.AU

12 mei 2026, 22:08 UTC

Winsten

CBA 3Q Loan Impairment Expense A$316M>CBA.AU

12 mei 2026, 22:07 UTC

Winsten

CBA: Costs Up on Higher Cloud Computing Volumes, Software Licenses, AI Investment>CBA.AU

12 mei 2026, 22:06 UTC

Winsten

CBA 3Q Operating Expenses Up 1% Excluding Restructuring, Notable Items>CBA.AU

12 mei 2026, 22:06 UTC

Winsten

CBA: 3Q Underlying Net Interest Margin Was Broadly Stable>CBA.AU

12 mei 2026, 22:05 UTC

Winsten

CBA: Lending, Deposit Volume Growth Offset Impact of Two Fewer Days >CBA.AU

12 mei 2026, 22:04 UTC

Winsten

Commonwealth Bank: Operating Income Flat in March Quarter >CBA.AU

12 mei 2026, 22:04 UTC

Winsten

Commonwealth Bank 3Q Cash Profit Up 4% on Year>CBA.AU

12 mei 2026, 22:04 UTC

Winsten

Commonwealth Bank 3Q Cash Profit Down 1% on 1H Quarterly Average>CBA.AU

Peer Vergelijking

Prijswijziging

Pulse Biosciences Inc Prognose

Koersdoel

By TipRanks

28.76% opwaarts potentieel

12 Maanden Prognose

Gemiddelde 30 USD 28.76%

Hoogste 30 USD

Laagste 30 USD

Gebaseerd op 2 Wall Street-analisten die 12-maands prijsdoelen bieden voor Pulse Biosciences Inc - Dist. in de afgelopen 3 maanden.

Beoordelingsconsensus

By TipRanks

Buy

2 ratings

Buy

Hold

Sell

Gebaseerd op 2 analisten die aandelenratings hebben gegeven aan Pulse Biosciences Inc - Dist in de afgelopen 3 maanden.

Technische score

By Trading Central

16.59 / 17.17Steun & Weerstand

Recent bearish events outweigh bullish events.

Sentiment

By Acuity

150 / 346 Rangschikking in Gezondheidszorg

Financieel

Verkoop- en administratiekosten

Bedrijfskosten

Winst voor belastingen

Verkoop

Kosten van verkopen

Brutowinst op verkopen

Rente-uitgaven op schulden

EBITDA

Operationele winst

Over Pulse Biosciences Inc

Pulse Biosciences, Inc. operates as a novel bioelectric medicine company. The company offers CellFX System, a tunable, software-enabled, and console-based platform that delivers nano second duration pulses of electrical energy to non-thermally clear targeted cells while sparing adjacent non-cellular tissue to treat a various medical condition by using its Nano-Pulse Stimulation technology. The company was formerly known as Electroblate, Inc. and changed its name to Pulse Biosciences, Inc. in December 2015. Pulse Biosciences, Inc. was incorporated in 2014 and is headquartered in Hayward, California.